PW Medtech Group Limited (01358) submitted a Next Day Disclosure Return dated 13 February 2026, indicating that its issued share capital remained at 1.47 billion shares as of 13 February 2026, unchanged from 6 February 2026.

According to the announcement, a total of 5.29 million shares were repurchased between 23 September 2025 and 13 February 2026 but had not yet been cancelled as of the closing balance date. Repurchase prices ranged from HKD 1.28 to HKD 1.56. On 13 February 2026 alone, 768,000 shares were repurchased on the Hong Kong Stock Exchange at a highest price of HKD 1.34 and a lowest price of HKD 1.32, for an aggregate paid amount of HKD 1.02 million.

The announcement also disclosed that the repurchase authorization was granted on 10 June 2025, covering up to 148.67 million shares. By 13 February 2026, a total of 18.44 million shares had been repurchased, representing 1.24% of the company’s issued shares under that mandate. A moratorium period for any new share issues stands in effect until 15 March 2026.